Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 9Magnetic Resonance Spectroscopy 6pembrolizumab 4Radiotherapy 4Nivolumab 4Fluorodeoxyglucose F18 4cabozantinib 3Specimen Handling 3Paclitaxel 3Melphalan 3Ipilimumab 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Busulfan 3lenvatinib 2entrectinib 2cediranib 2Thiotepa 2Sunitinib 2Radiation 2Peripheral Blood Stem Cell Transplantation 2Injections 2Ifosfamide 2FAPI-46 2Etoposide 2Carboplatin 2Bone Marrow Transplantation 2Bevacizumab 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2trioctyl phosphine oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × tariquidar × Genitourinary × Clear all
NCT00011414 2019-07-16

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
29 enrolled
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡